We hypothesized that an activating Kras mutation in the pancreas drives inflammation, which hijacks the physiological upregulation of HO-1 in macrophages, prolonging HO-1 expression and converting the physiological responses of macrophages for inflammation toward a tumor-promoting phenotype. The gene discussed is KRAS; the disease is neoplasm.